Board of Directors

Name Title Background
Rolf A. Classon Chairman of our Board
  • Served as interim President and Chief Executive Officer Of Xanodyne from April 2007 to July 2007.
  • Several positions with Bayer AG including Chairman of the Executive Committee of Bayer Healthcare
  • Chairman of the board of directors of Hillenbrand Industries, Inc. and Auxilium Pharmaceuticals, Inc.
  • Director of Millipore Corporation, Enzon Pharmaceuticals, Inc., PharmaNet Development Group, Inc. and Eurand N.V.
  • Degree in chemical engineering from the Gothenburg School of Engineering (Sweden) and a politices magister degree from the University of Gothenburg in Sweden
Michael J. Valentino CEO & President, Xanodyne Pharmaceuticals
  • President, Chief Executive Officer and a Director for Adams Respiratory Therapeutics, Inc., a specialty pharmaceutical company.
  • President and Chief Operating Officer for the Global Human Pharmaceutical Division of Alpharma Inc., a global specialty pharmaceutical company.
  • Executive Vice President, Global Head of Consumer Pharmaceuticals, for Novartis AG.
  • B.A. in psychology from the State University of New York at Stony Brook.
Vaughn Kailian Director
  • Managing Director of MPM Capital
  • Chairman of Elixir Pharmaceuticals Inc., Cerimon Pharmaceuticals Inc. and Veritas Inc.
  • CEO of COR Therapeutics, Inc.
  • U.S. and International general management positions at Marion Merrell Dow, Inc.
  • BA, Tufts University
  • Member of the Board for BIO Ventures for Global Health and the New England Healthcare Institute
Dennis Purcell Director
  • Senior Managing Director of Aisling Capital LLC, a private equity firm that advises the Perseus-Soros Biopharmaceutical Fund, LP.
  • Director of Auxilium Pharmaceuticals, Inc.
  • B.S. in economics and accounting from the University of Delaware and an M.B.A. from Harvard University.
Steven St. Peter, M.D. Director
  • Several positions at MPM Capital, a venture capital firm specializing in the life sciences industry, including General Partner since June 2005.
  • Principal of Apax Partners, a private equity firm that invests in various industry sectors, including the healthcare industry.
  • Senior Associate at the Carlyle Group, a private equity firm that invests in various industry sectors, including the healthcare industry.
  • Director of PharmAthene, Inc., Helicos BioSciences Corporation and Omrix Biopharmaceuticals, Inc.
  • B.A. in chemistry from the University of Kansas, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from Washington University.
  • Board certified in internal medicine.
Patrick Enright Director
  • Co-Founder and Managing Director, Longitude Capital
  • Managing Director, Pequot Ventures
  • Managing Member, Delta Opportunity Fund
  • CFO & SVP Business Development positions at Valentis and Boehringer Mannheim Pharmaceuticals
  • Member of the Board for Corcept Therapeutics (NASDAQ: CORT), Jazz Pharmaceuticals (NASDAQ: JAZZ) and multiple privately-held companies.
  • B. S. in biological sciences from Stanford University and an M.B.A. from the Wharton School of Business at the University of Pennsylvania
Craig A. Tooman Director
  • Executive Vice President, Finance and Chief Financial Officer of Enzon Pharmaceuticals, Inc., a biopharmaceutical company.
  • Senior Vice President of Strategic Planning and Corporate Communications for ILEX Oncology, Inc., a biopharmaceutical company.
  • Masters degree in finance from the University of Chicago.
James Shannon, M.D. Director
  • Present - CEO and President of Cerimon Pharmaceuticals, Inc.
  • Head of Pharma Development for Novartis AG
  • Head of Drug Registration and Regulatory Affairs for Sandoz
  • MD – Queen’s University of Belfast
  • Member of the Royal College of Physicians
    (UK) in 1983